CJ CheilJedang Corp.

Investors have been flocking to the worldwide biotech sector over the past few years amid high returns and as a result initial public offerings in the sector have also attracted strong interest. But s

Biologics contract development and manufacturing organizations (CDMO) have emerged as top merger and acquisition targets in the global biopharma industry and South Korean firms are actively taking par

While global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. CJ CheilJedang Acquires Batavia To Expa